Business Wire

Objectway Supports Baader Bank to Propel Its 'Road to Future' Program

Share

Baader Bank, a leading European provider of securities and banking services, has committed to Objectway for its strategic “Road to Future” program to implement a future-proof, highly scalable, and operationally frictionless core banking environment over the next three years.

Building on their long-standing and successful partnership back to 2010, the bank has experienced rapid and significant growth driven by its innovative business model. Such a dynamic growth requires constant enhancements to future-proof the bank's operations and keep pace with its continuous expansion.

To address these evolving needs, both parties have embraced a strategic plan entitled "Road to Future". Over the next three years, the program aims to further support Baader Bank and its core banking infrastructure in driving towards a future-proof, highly scalable and operationally efficient platform.

The project will optimize the processing of an increasing volume of transactions, including payments, while streamlining the generation of customer reports and documentation. This transformation will position the bank for greater scalability and agility, with the potential to move to a SaaS or Cloud operating model in the mid-term.

Effective delivery and strong governance

The successful delivery of the “Road to Future” program will rely on the commitment of both Baader Bank and Objectway, supported by detailed planning and a comprehensive project organization and governance structure.

Objectway will employ its proven Solution Design procedure to ensure a systematic approach to problem analysis and solution delivery. This process includes a thorough examination of the bank's pain points, operational needs, and constraints to derive actionable epics for the implementation phase. An agile development methodology will be adopted, testing various strategies to identify the most effective solutions.

The final stage will involve a thorough review of all developed solutions, ensuring the optimal strategies are implemented.

“This is Objectway’s standard, well-proven approach, ensuring strong project control, management and transparency, ongoing support and timely delivery,” said Karl im Brahm, CEO of Objectway for the DACH region. “In light of the increasing importance of flexibility for core banking systems, we are dedicated to acting as a trusted orchestrator in pursuit of solutions that meet the evolving demands of the market. This includes ensuring technical adaptability, functional scalability and regulatory compliance.”

The strategic initiative will further strengthen Baader Bank’s positioning as a reliable and future-focused leader in the securities and banking sector. By enhancing scalability and operational efficiency, the program paves the way for new business opportunities and increased capacity, marking another significant milestone in the long-standing partnership between Baader Bank and Objectway.

As the program progresses, additional enhancements will continue to elevate Baader Bank’s service offerings, reinforcing Objectway’s pivotal role in driving innovation and excellence within the financial industry.

Nico Baader, CEO of Baader Bank, commented, “In recent years, Baader Bank has consistently optimized its platform with a focus on future growth in the securities and brokerage sectors, while continuously investing in innovation. Through the 'Road to Future' program, Baader Bank is positioning itself as a leading partner for securities and banking services in Europe. We are delighted to share this vision with Objectway and to realize it together as planned.”

View source version on businesswire.com: https://www.businesswire.com/news/home/20250124066216/en/

Contacts

Chiara Giudici
+393938229579
chiara.giudici@objectway.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

REPLY: Coding and Cybersecurity, Registration Is Now Open for the Reply Hack The Code Challenge 202531.1.2025 13:42:00 EET | Press release

Reply has announced the opening of registrations for the ReplyHackThe Code Challenge 2025, the leading online team coding competition, which will take place on March 12th 2025. This year's challenge will combine programming and cybersecurity for the first time, offering participants the opportunity to tackle algorithmic problems and cybersecurity challenges. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250131992792/en/ Reply has announced the opening of registrations for the Reply Hack The Code Challenge 2025, the leading online team coding competition, which will take place on March 12th 2025. This year's challenge will combine programming and cybersecurity for the first time, offering participants the opportunity to tackle algorithmic problems and cybersecurity challenges. (Photo: Business Wire) The competition follows the format of previous events, with two parallel challenges: the Standard Edition, aimed at university

GE HealthCare Invests $138 Million in Cork, Ireland Manufacturing Facility to Address Increasing Contrast Media Demand31.1.2025 10:00:00 EET | Press release

GE HealthCare (Nasdaq: GEHC) today announced a $138 million investment to expand its Carrigtohill, Cork contrast media fill and finish manufacturing site in Ireland. A new state-of-the-art facility on the grounds of the existing site will enable 25 million more patient doses per year of contrast media by the end of 2027, helping address growing global demand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250130241464/en/ GE HealthCare’s contrast media manufacturing site in Cork (Photo: Business Wire) Contrast media are injectable diagnostic imaging agents used to enhance visualization of organs, blood vessels and tissues during medical imaging. Global demand for iodine-based contrast media, used in X-Ray, Computed Tomography (CT) and Interventional procedures is expected to double in the next decade, driven by ageing populations and the increasing global prevalence of chronic disorders. In 2024, the Carrigtohill facility, a

Vertex Announces CASGEVY ® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England31.1.2025 09:00:00 EET | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). The reimbursement agreement comes as the National Institute for Health and Care Excellence (NICE) issues positive guidance recommending CASGEVY’s use in the NHS. It means that eligible SCD patients in England now have access to the therapy following the prior agreement for transfusion-dependent beta thalassemia (TDT) patients announced last August. “Today is an important day for the sickle cell community who have gone too long without treatments that address the underlying cause of their devastating disease,” said Ludovic Fenaux, Senior Vice President, Vertex International. “We are pleased to have reached this new agreement that ensures both eligible SCD and TDT patients can now be treated with CASGEVY, recognizing the value a one-time treatment can provide to

IMCAS 2025: New Galderma Phase IIIb Data Reinforce Rapid Onset and Long-lasting Aesthetic Improvement with RelabotulinumtoxinA (Relfydess™)31.1.2025 08:00:00 EET | Press release

Galderma (SWX:GALD), the pure-play dermatology category leader, announced today results from its new phase IIIb RELAX clinical trial demonstrating the rapid onset and the long-lasting duration of aesthetic efficacy, as well as high patient satisfaction and increased confidence, using a single-dose of RelabotulinumtoxinA (Relfydess) to treat frown lines (glabellar lines)1. Galderma’s analysis was presented at the International Master Course on Aging Science (IMCAS) 2025 annual congress, held in Paris from January 30 to February 1, 2025. Developed and manufactured by Galderma, RelabotulinumtoxinA is the first and only ready-to-use liquid neuromodulator created with PEARL Technology that is designed to preserve molecule integrity to deliver a highly active, innovative, complex-free molecule3,4,5.Previously announced data from the phase III READY clinical trial program demonstrated rapid onset as soon as Day 1 (reported by up to 39% of subjects) and long-lasting efficacy for 6 months (main

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain31.1.2025 01:25:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain. JOURNAVX is an effective, well-tolerated medicine without evidence of addictive potential indicated for use across all types of moderate-to-severe acute pain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250109747971/en/ JOURNAVX bottle and tablet (Photo: Business Wire) “Today’s approval is a historic milestone for the 80 million people in America who are prescribed a medicine for moderate-to-severe acute pain each year,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “With the approval of JOURNAVX, a non-opioid, pain signal inhibitor and the first new class of pain medicine approved in more than 20 years, we h

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye